Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has announced its plans to release second quarter 2024 financial results after market close on Thursday, August 8, 2024. The company will host an investor conference call on the same day at 5:00 p.m. ET to discuss financial results and business highlights.
Investors can access the conference call by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) with the conference ID 1679035. A live audio webcast and accompanying slide presentation will be available in the Investor Relations section of Anika's website at www.anika.com. The call will be archived and accessible on the website shortly after its conclusion.
Anika Therapeutics (NASDAQ: ANIK), un'azienda globale specializzata nella preservazione delle articolazioni e nell'ortopedia interventistica precoce, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 dopo la chiusura del mercato giovedì 8 agosto 2024. L'azienda ospiterà una conference call per gli investitori lo stesso giorno alle 5:00 p.m. ET per discutere i risultati finanziari e i punti salienti dell'attività.
Gli investitori possono accedere alla conference call componendo il numero 1-800-717-1738 (numero verde nazionale) oppure 1-646-307-1865 (internazionale) con l'ID conferenza 1679035. Un webcast audio dal vivo e una presentazione con diapositive saranno disponibili nella sezione Relazioni con gli Investitori del sito web di Anika all'indirizzo www.anika.com. La chiamata sarà registrata e accessibile sul sito dopo la sua conclusione.
Anika Therapeutics (NASDAQ: ANIK), una compañía global dedicada a la conservación de articulaciones y especializada en ortopedia de intervención temprana, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 después del cierre del mercado el jueves 8 de agosto de 2024. La empresa realizará una conferencia telefónica con inversores el mismo día a las 5:00 p.m. ET para discutir los resultados financieros y los puntos destacados del negocio.
Los inversores pueden acceder a la conferencia telefónica marcando el 1-800-717-1738 (número gratuito nacional) o el 1-646-307-1865 (internacional) con el ID de conferencia 1679035. Se dispondrá de una transmisión en vivo y una presentación de diapositivas en la sección de Relaciones con Inversores del sitio web de Anika en www.anika.com. La llamada será archivada y accesible en el sitio poco después de su finalización.
Anika Therapeutics (NASDAQ: ANIK), 조기 개입 정형외과 분야에 특화된 글로벌 관절 보존 회사는 2024년 2분기 재무 결과를 2024년 8월 8일 목요일 시장 종료 후 발표할 계획을 발표했습니다. 회사는 같은 날 오후 5:00 ET에 재무 결과 및 비즈니스 주요 내용을 논의하기 위한 투자자 컨퍼런스 콜을 개최합니다.
투자자들은 1-800-717-1738 (국내 무료) 또는 1-646-307-1865 (국제)로 전화를 걸어 1679035 회의 ID로 컨퍼런스 콜에 접속할 수 있습니다. 라이브 오디오 웹캐스트 및 슬라이드 프레젠테이션은 Anika의 웹사이트 투자자 관계 섹션에서 www.anika.com 확인할 수 있습니다. 이 통화는 종료 후 곧 웹사이트에서 아카이브되어 접근 가능할 것입니다.
Anika Therapeutics (NASDAQ: ANIK), une entreprise mondiale spécialisée dans la préservation des articulations et l'orthopédie d'intervention précoce, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 après la fermeture du marché le jeudi 8 août 2024. L'entreprise tiendra une conférence téléphonique pour les investisseurs le même jour à 17h00 ET pour discuter des résultats financiers et des points saillants de son activité.
Les investisseurs peuvent accéder à la conférence téléphonique en composant le 1-800-717-1738 (numéro vert national) ou le 1-646-307-1865 (international) avec l'ID de conférence 1679035. Un webinaire audio en direct et une présentation de diapositives seront disponibles dans la section Relations avec les investisseurs du site web d'Anika à l'adresse www.anika.com. L'appel sera archivé et accessible sur le site peu après sa conclusion.
Anika Therapeutics (NASDAQ: ANIK), ein globales Unternehmen zur Erhaltung von Gelenken, das sich auf eine frühe Intervention in der Orthopädie spezialisiert hat, hat seine Pläne angekündigt, die Finanzergebnisse des zweiten Quartals 2024 am Donnerstag, dem 8. August 2024, nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 17:00 Uhr ET eine Telefonkonferenz für Investoren abhalten, um die finanziellen Ergebnisse und Geschäftshighlights zu besprechen.
Investoren können an der Telefonkonferenz teilnehmen, indem sie 1-800-717-1738 (kostenlose nationale Nummer) oder 1-646-307-1865 (international) anrufen und die Konferenz-ID 1679035 eingeben. Ein Live-Audio-Webcast und die dazugehörige Präsentation werden im Bereich für Investorenbeziehungen auf der Website von Anika unter www.anika.com verfügbar sein. Die Aufnahme des Anrufs wird kurz nach dem Ende auf der Website zugänglich sein.
- None.
- None.
BEDFORD, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2024 financial results after the close of the market on Thursday, August 8, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 1679035. A live audio webcast will be available in the Investor Relations section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com
FAQ
When will Anika Therapeutics (ANIK) release its Q2 2024 financial results?
What time is Anika's (ANIK) Q2 2024 earnings call scheduled for?
How can investors access Anika's (ANIK) Q2 2024 earnings call?
Where can investors find Anika's (ANIK) Q2 2024 earnings presentation?
